14th Annual Hawaii Gastroenterology Symposium
PROGRAM CHAIR:
Stanley S. Shimoda, MD
Associate Professor of Medicine
Chief, Division of Gastroenterology
John A. Burns School of Medicine
University of Hawaii


SYMPOSIUM FACULTY:
Margaret M. Heitkemper, PhD, RN, FAAN
Professor and Chair
Department Of Biobehavioral Nursing & Health Systems
Professor, Division of Gastroenterology
University of Washington


Nimish Vakil, MD
Professor of Medicine
University of Wisconsin School of Medicine and Public Health


John M. Vierling, MD, FACP
Professor of Medicine and Surgery
Director, Baylor Liver Health
Chief of Hepatology
Baylor College of Medicine
Director of Advanced Liver Therapies
St. Luke’s Episcopal Hospital
Course Objectives: At the conclusion of the program, attendees will:
  1. Know the probability of obtaining sustained virological responses for patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infections associated with different genotypes, viral loads, body weights, co-infections and races. Understand the new antiviral agents being developed for treatment of chronic hepatitis C and the design of the clinical trials of these agents. Be able to identify patients with either HBeAg-positive or HBeAg-negative hepatitis B virus infections who should be treated and the pros and cons of each of the FDA-approved antiviral therapies. Identify patients with either HCV or HBV infection who should have serial surveillance for hepatocellular carcinoma.
  2. Describe the role of visceral hypersensitivity in the etiology and pathophysiology of irritable bowel syndrome (IBS). Contrast current drug therapies used in the management of IBS. Identify the role of non-pharmacological therapies in the management of IBS.
  3. Describe the new global definition and classification of GERD. Examine new data on the relationship between GERD and extra-esophageal disorders. Discuss the risks and long term benefits of therapy for GERD.

Target Audience: This symposium for primary care physicians and other interested physicians, will address three topics: Update on Hepatitis B and C, Update on IBS and Update on GERD.
Hawaii Prince Hotel
Mauna Kea Ballroom
100 Holomoana Street
Honolulu, Hawaii

Saturday, January 27, 2007
12:00 noon - 5:15 pm
Space is limited.
There is no charge for this program, but pre-registration by fax or email is required. Deadline for receipt of registration is January 19, 2007. Late registration will be accommodated on a space available basis. To confirm space availability, Please call IME's corporate headquarter (800) 905-2033 or e:mail us.

Please see the official brochure for more details.
Specialty: *
Title: *
First Name: *
Middle Name: *
Last Name: *
Address: *
City: *
State: *
Zip Code: *
Business Phone: *
Business Fax: *
Email Address: *
* - Required
Accreditation Statement:
The Institute for Medical EducationSM is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. The Institute for Medical EducationSM takes responsibility for the content, quality and scientific integrity of this CME activity.

Credit Designation Statement:
The Institute for Medical EducationSM designates this educational activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

In accordance with the ACCME’s revised Standards of Commercial Support, potential conflicts of interest are thoroughly vetted by the Executive Committee of IME. All conflicts are resolved prior to the beginning of the activity by the IME peer review process. The opinion expressed in this activity are those of the faculty and do not necessarily reflect those of IME.

Provider approved by the California Board of Registered Nursing, provider number 10672 for a maximum of 4 contact hour(s).

This activity is supported by an unrestricted educational grant from:

AstraZeneca
Novartis
Roche Laboratories
Bristol-Myers Squibb